



MINNEAPOLIS, MN and SCOTTSDALE, AZ June 6, 2024 /PRNewswire/ -- Premier Biotech, LLC (“Premier”), one of the nation's leading toxicology solutions providers, today announced that it has completed the acquisition of Desert Tox LLC, a laboratory testing provider certified by the Substance Abuse and Mental Health Services Administration (“SAMHSA”).

With strategic locations from the Midwest to the Southwest and West, the combined Premier and Desert Tox organization will be ideally positioned to support its nationwide customer base with a broad range of toxicology solutions and actionable results.

“This is a highly strategic acquisition for Premier, yielding a new partnership that strengthens our shared expertise and capabilities to serve key customers in the emerging oral fluid market, both at the product and laboratory levels,” said Premier’s Chief Executive Officer Cindy Horton. “Our combined platform is not only better poised to help our customers manage drugs of abuse testing in the workplace and government sectors, but we are now well positioned to move strongly into evolving wellness and infectious disease markets.”

“We are pleased to welcome Desert Tox’s founders, Mike Grommes and Mike Gorman, as we work together to ensure a successful transition aimed at continued market growth.”

The newly combined entities yield an industry-leading organization capable of operating throughout the contiguous United States and enables Premier to expand its employer-based solutions throughout the country. With the acquisition of Desert Tox and the recent DOT guidelines permitting oral fluid for regulated employment testing, the company will be in a position to offer both regulated and non-regulated oral fluid testing solutions. “This union creates an unparalleled network of the best and most reliable toxicology solutions providers in our field,” Ms. Horton said.

This joining of forces is Premier’s first acquisition since it was acquired by Align Capital Partners in November 2022. ACP Managing Partner Rob Langley, Operating Partner Ervin Cash, Vice President Matt Bowen and Associate Sarah Mahosky worked with Premier to complete the Desert Tox transaction.

About Premier Biotech

Premier Biotech delivers rapid and innovative diagnostic solutions that promote health, safety and compliance. The Company is a leading provider of proprietary oral fluid (OralTox® and OT-Scan®) and other products, services and technology solutions that are designed to simplify and provide a seamless end-to-end experience for customers. Premier differentiates itself through its fully integrated service offering that is augmented with high levels of service, technical expertise and customization. The Company’s integrated offering is utilized in workplace (pre-employment and post-employment), government (child and family services, probation, parole, corrections, law enforcement and DOT) and healthcare settings. For more information, visit [innovation.premierbiotech.com](https://www.innovation.premierbiotech.com)